GlassScriptPhysician profile
Miranda D Withers
NPI 1427369206
$17,033.20
in general payments reported to CMS, 2019-2025
22 companies · $4,575 in 2025
The $4,575 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,844 · 2022: $6,682 · 2023: $1,821 · 2024: $2,112 · 2025: $4,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,448 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,010 · Travel and Lodging: $1,520 · Education: $329 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,447.97 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,010.00 |
| Travel and Lodging | $1,520.31 |
| Education | $329.07 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $12,011.79 | 2021-2025 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $961.68 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Mylan Specialty L.P. | $529.71 | 2022-2024 | Yupelri |
| Viatris Specialty LLC | $450.93 | 2025 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $444.96 | 2021-2025 | Tezspire, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $374.24 | 2021-2024 | Ofev, Spiriva Respimat |
| Jazz Pharmaceuticals INC. | $345.09 | 2024-2025 | |
| Harmony Biosciences LLC | $341.23 | 2022-2025 | Wakix |
| Amgen INC. | $335.90 | 2024-2025 | Tezspire |
| Grifols Shared Services North America, INC. | $240.00 | 2023 | Prolastin-C Liquid |
| Avadel Cns Pharmaceuticals, LLC | $200.00 | 2025 | Lumryz |
| Sunovion Pharmaceuticals INC. | $184.76 | 2021 | |
| Inspire Medical Systems, INC. | $154.88 | 2024-2025 | Inspire |
| Verona Pharma, INC. | $133.33 | 2025 | Ohtuvayre |
| Electromed, INC. | $117.78 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $67.10 | 2021-2023 | Keytruda |
| Idorsia Pharmaceuticals US INC | $45.16 | 2023 | Quviviq |
| Ucb, INC. | $22.23 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.51 | 2023 | Lifevest |
| Paratek Pharmaceuticals, INC. | $20.18 | 2025 | Nuzyra |
| Optinose US, INC. | $16.16 | 2024 | |
| Covis Pharma Gmbh | $14.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Withers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.